Amongst its mechanisms, genistein has shown a growth-inhibitory effect on human cholangiocarcinoma cells by reducing AKT and EGFR activation, as well as IL6 production, involving both oestrogen and oestrogen receptors, while also inhibiting inflammatory cell migration. Here, EGFR is linked to cholangiocarcinoma.